EGMN -- Rilpivirine, an investigational non-nucleoside reverse transcriptase inhibitor for treating HIV, matched the efficacy of the benchmark agent in the class, efavirenz, and edged efavirenz for safety in a pair of phase III studies with more than 1,300 patients combined.
